Elekta to address Indonesia's cancer care gap with direct presence
Elekta (EKTA-B.ST) has established a permanent presence in Jakarta, Indonesia, to enhance cancer care access. With over 275 million residents and fewer than 80 active linear accelerators, Indonesia faces a critical gap in radiation therapy resources. Elekta aims to address this by improving service, support, and order fulfillment for customers, ultimately enhancing treatment options for patients. This initiative underscores Elekta's commitment to organic growth and meeting the demand for modern cancer care in underserved markets.
- Elekta aims to improve cancer care access in Indonesia, a highly underserved market.
- Establishment of a direct presence allows enhanced service and support for customers.
- None.
STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) announced today that is has established permanent legal entity in Indonesia's capital, Jakarta in order to address the unmet need for high quality, modern cancer care.
Radiation therapy is a critical component in treating cancer and is considered necessary in the treatment of over half of all cancer patients[1]. However, according to GLOBOCAN[2], more than 15,000 linear accelerators are required globally to close the gap between countries with sufficient cancer resources and those without. Indonesia, for example, has fewer than 80 active devices[3] serving a population of almost 275 million inhabitants.
Shaun Seery, Elekta's Senior Vice President Asia Pacific, says, "Indonesia is a highly underserved market when it comes to radiation therapy. Our ambition is to close the gap through organic growth and establish a presence where we will make an impact. This direct presence will allow us to support customers and ensure they can offer their patients access to the best cancer care available."
Elekta, the market leader in Indonesia, aims to provide customers with enhanced service, support, and order fulfilment, as well as access to the latest education and training.
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta:
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,400 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
[1] https://doi.org/10.1016/j.clon.2021.05.008
[2] Ferlay J, et al. Global Cancer Observatory: Cancer Tomorrow. Lyon: International Agency for Research on Cancer, 2020; UN World Population Prospects 2019; International Atomic Energy Agency: DIRAC (Directory of Radiotherapy Centres), 2021
[3] https://doi.org/10.1016/j.radonc.2020.05.044
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Indonesia_direct presence 2021_final |
View original content:https://www.prnewswire.com/news-releases/elekta-to-address-indonesias-cancer-care-gap-with-direct-presence-301362384.html
SOURCE Elekta
FAQ
What is Elekta's announcement regarding Indonesia on August 25, 2021?
How many residents in Indonesia are served by the existing linear accelerators?
What gaps in cancer care does Elekta address in Indonesia?
What is Elekta's market position in Indonesia?
